THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Lucila Garcia-Contreras to Animals

This is a "connection" page, showing publications Lucila Garcia-Contreras has written about Animals.
Connection Strength

0.900
  1. Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008.
    View in: PubMed
    Score: 0.066
  2. Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples. J Pharm Biomed Anal. 2019 Jun 05; 170:124-131.
    View in: PubMed
    Score: 0.062
  3. Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186.
    View in: PubMed
    Score: 0.059
  4. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. Int J Pharm. 2018 Oct 05; 549(1-2):306-316.
    View in: PubMed
    Score: 0.059
  5. Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. Eur J Pharm Biopharm. 2018 Sep; 130:272-280.
    View in: PubMed
    Score: 0.059
  6. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. J Pharm Sci. 2018 02; 107(2):638-646.
    View in: PubMed
    Score: 0.056
  7. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. J Pharm Sci. 2017 01; 106(1):331-337.
    View in: PubMed
    Score: 0.052
  8. Liquid chromatographic determination of CPZEN-45, a novel anti-tubercular drug, in biological samples. J Pharm Biomed Anal. 2014 Jan; 88:370-6.
    View in: PubMed
    Score: 0.042
  9. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther Deliv. 2013 Aug; 4(8):1027-45.
    View in: PubMed
    Score: 0.042
  10. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol. 2012; 2:118.
    View in: PubMed
    Score: 0.039
  11. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother. 2012 May; 56(5):2612-8.
    View in: PubMed
    Score: 0.038
  12. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2010 Apr; 54(4):1436-42.
    View in: PubMed
    Score: 0.033
  13. Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A. 2008 Mar 25; 105(12):4656-60.
    View in: PubMed
    Score: 0.029
  14. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007 Sep 30; 59(11):1133-51.
    View in: PubMed
    Score: 0.028
  15. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug; 51(8):2830-6.
    View in: PubMed
    Score: 0.027
  16. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother. 2006 Nov; 58(5):980-6.
    View in: PubMed
    Score: 0.026
  17. Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications. Int J Mol Sci. 2023 May 03; 24(9).
    View in: PubMed
    Score: 0.021
  18. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci. 2003; 5(2):E9.
    View in: PubMed
    Score: 0.020
  19. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm Res. 2001 Dec; 18(12):1685-93.
    View in: PubMed
    Score: 0.019
  20. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit Rev Ther Drug Carrier Syst. 2001; 18(4):387-431.
    View in: PubMed
    Score: 0.017
  21. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
    View in: PubMed
    Score: 0.016
  22. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570.
    View in: PubMed
    Score: 0.014
  23. Isoxyl assays in plasma. J Pharm Biomed Anal. 2012 Feb 23; 60:1-6.
    View in: PubMed
    Score: 0.009
  24. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 2010 Dec; 12(4):699-707.
    View in: PubMed
    Score: 0.009
  25. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 2010 Sep; 12(3):338-47.
    View in: PubMed
    Score: 0.008
  26. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010 Sep; 12(3):330-7.
    View in: PubMed
    Score: 0.008
  27. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009 Aug; 26(8):1847-55.
    View in: PubMed
    Score: 0.008
  28. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. AAPS J. 2009 Mar; 11(1):139-47.
    View in: PubMed
    Score: 0.008
  29. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother. 2009 Apr; 53(4):1338-43.
    View in: PubMed
    Score: 0.008
  30. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res. 2008 Apr; 25(4):805-11.
    View in: PubMed
    Score: 0.007
  31. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm Res. 2007 Oct; 24(10):1834-43.
    View in: PubMed
    Score: 0.007
  32. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm Res. 2001 Dec; 18(12):1677-84.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES